Keros Therapeutics (KROS) Net Margin (2019 - 2025)
Historic Net Margin for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to 51.04%.
- Keros Therapeutics' Net Margin rose 135974100.0% to 51.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.12%, marking a year-over-year increase of 279170600.0%. This contributed to the annual value of 5277.55% for FY2024, which is 960416600.0% up from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' Net Margin is 51.04%, which was up 135974100.0% from 168.96% recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Net Margin ranged from a high of 1588500.0% in Q1 2021 and a low of 493000.0% during Q3 2023
- Moreover, its 5-year median value for Net Margin was 1513.02% (2024), whereas its average is 66306.99%.
- As far as peak fluctuations go, Keros Therapeutics' Net Margin crashed by 2000000000bps in 2022, and later surged by 2000000000bps in 2024.
- Quarter analysis of 5 years shows Keros Therapeutics' Net Margin stood at 38.77% in 2021, then crashed by -247bps to 134.37% in 2022, then crashed by -20844bps to 28141.96% in 2023, then soared by 95bps to 1513.02% in 2024, then surged by 97bps to 51.04% in 2025.
- Its last three reported values are 51.04% in Q3 2025, 168.96% for Q2 2025, and 70.27% during Q1 2025.